drugset

Drugs / MP0310

Follow last change Dec 2022 re-read 3 minutes ago

MP0310

Protein / enzyme biologic

Developed for: neoplasm
Investigated by: Molecular Partners AG

Trials 1

today NCT04049903 · Ph 1

2020202120222023202420252026

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Phase 1	NCT04049903	Sep 2019 → Jun 2022	neoplasm	Molecular Partners AG	Completed	No outcome recorded

News releases announcing trial results or a regulatory action · 1

Date	Issuer	Release
2020-12-17	Molecular Partners AG	Results Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy molecularpartners.com ↗ First-in-human data from ongoing phase 1 study of MP0310 (AMG 506) demonstrate encouraging biological activity, including successful localized tumor engagement and saturation

All press releases naming this drug 7 releases

Date	Issuer	Release
2022-04-26	Molecular Partners AG	Molecular Partners to Regain Global Rights for MP0310 from Amgen molecularpartners.com ↗
2020-12-17	Molecular Partners AG	Molecular Partners Announces New Clinical Data, Immunomodulation Platform Advances, and Virology Portfolio Strategy molecularpartners.com ↗
2020-05-15	Molecular Partners AG	Molecular Partners to Present Preclinical Data from MP0317, AMG 506 / MP0310 and Peptide-MHC Programs at AACR Annual Meeting molecularpartners.com ↗
2019-10-31	Molecular Partners AG	INTERIM MANAGEMENT STATEMENT – Q3 2019: Encouraging Additional Phase 3 Data Presented for Abicipar, and Start of Phase 1 Trial for MP0310, the First Immuno-oncology DARPin® with a Novel Therapeutic Design molecularpartners.com ↗
2019-10-03	Molecular Partners AG	Molecular Partners Announces First Patient Dosed in Phase 1 Trial of MP0310, a Novel Tumor-Localized Immunotherapy molecularpartners.com ↗
2019-08-27	Molecular Partners AG	Molecular Partners reports key financials for H1 19 and corporate highlights: EMA has validated the marketing authorization application for abicipar; Focus of MP0250 on multiple myeloma with expected initiation of ph2 IMiD trial in Q4 19; MP0310 ph1 start on track for H2 19 molecularpartners.com ↗
2018-04-05	Molecular Partners AG	Molecular Partners to present MP0310 pre-clinical data and MP0250 clinical abstracts at the AACR Annual Meeting 2018 molecularpartners.com ↗

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

Field	Value	Cited text
Known as	MP0310	ClinicalTrials.gov intervention name — accepted as the source's own label NCT04049903 ↗
Modality	Protein / enzyme biologic	“MP0310, a DARPin® therapeutic candidate for tumor targeted activation of T cells” NCT04049903 ↗